Bray JJH, Foster‐Davies H, Salem A, et al. - Researchers investigated how Glucagon‐Like Peptide‐1 Receptor Agonists (GLP‐1RAs) can impact clinical biomarkers of inflammation and oxidative stress, by performing this meta‐analysis and systematic review. Randomised controlled trials assessing alterations with GLP‐1RAs in a priori selected biomarkers of inflammation were identified from Medline, Embase and The Cochrane Library. Study of GLP‐1RAs compared with standard diabetes therapies or placebo demonstrated significant decreases in c‐reactive protein (CRP), tumour necrosis factor‐alpha and malondialdehyde, and significant rises in adiponectin. HOMA‐IR, but not glycated haemoglobin, was identified to be significantly correlated with a decrease in CRP. Experts found strong evidence that GLP‐1RAs exert clinically relevant anti‐inflammatory and antioxidant impacts.